Cannabinoid Quinone Derivatives for PPARγ Agonism
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current PPARγ agonists exhibit low efficiency in binding to PPARγ and often have high toxicity, limiting their effectiveness in treating PPARγ-related diseases.
Innovation Solution
Development of cannabinoid quinone derivatives, such as CBG-Q and FM-CBD-Q, which are synthesized from natural cannabinoids like CBD and CBG, featuring specific radicals that enhance binding affinity to PPARγ and reduce cytotoxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current PPARγ agonists are used to treat PPARγ-related diseases, then therapeutic effect is achieved, but toxicity increases
Solution Approach 1:
The patent modifies the chemical structure of cannabinoid compounds by introducing quinone derivatives and specific radical substitutions (R1, R2, R3 groups) to change the binding parameters of PPARγ agonists. This structural parameter change enhances binding affinity and selectivity, improving therapeutic efficacy while reducing off-target toxicity effects
Solution Approach 2:
The invention creates composite chemical structures by combining cannabinoid core structures with quinone functional groups and various substituent radicals. This composite approach generates new molecules that maintain the beneficial PPARγ agonistic activity of cannabinoids while the quinone moiety provides improved pharmacokinetic properties and reduced toxicity
2Reliability
If current PPARγ agonists are used to treat PPARγ-related diseases, then therapeutic effect is achieved, but binding efficiency remains low
Solution Approach 1:
The patent systematically varies chemical parameters including the type of radical substituents (R1=H, OH, CHO, COOH; R2=cyclohexene, alkene; R3=OH, OCH3), the position of substitution, and the quinone ring structure to optimize binding efficiency. These parameter changes result in derivatives with significantly enhanced PPARγ binding affinity compared to parent cannabinoids
Solution Approach 2:
The invention introduces specific local modifications at particular positions on the cannabinoid molecule (positions indicated by R1, R2, R3 substituents). These localized quality changes at specific molecular sites enhance the interaction with PPARγ binding pockets, improving binding efficiency without compromising overall molecular stability
Data Source
AI summary
Cannabinoid quinone derivatives. The present invention refers to cannabinoid quinone derivatives to be used as medicaments, particularly as PPAR gamma (PPARg) agonists for treating diseases which etiology is based on an impaired PPARg function as transcription factor i.e. PPARg-related diseases.